Top Buy
| Security | Buy | Sell | Buy (1M) ▼ | Sell (1M) | Price | Target price | Potential |
|---|---|---|---|---|---|---|---|
| Alnylam Pharmace. | 47 | 0 | 11 | 0 | €231.70 | €251.80 | 8.676% |
| Canopy Growth Corp | 9 | 0 | 5 | 0 | €0.47 | €1.75 | 273.134% |
| Arrowhead Pharmaceuticals Inc. | 21 | 2 | 5 | 0 | €23.26 | €54.94 | 136.195% |
| Xencor Inc. | 14 | 1 | 4 | 0 | €16.90 | €31.70 | 87.553% |
| QIAGEN NV | 11 | 0 | 3 | 0 | €40.47 | €47.44 | 17.223% |
| Taro Pharmaceutical Industries Ltd | 10 | 0 | 3 | 0 | €40.00 | - | - |
| Evotec SE | 6 | 2 | 3 | 1 | €9.81 | €19.00 | 93.680% |
| Halozyme Therapeutics Inc. | 20 | 0 | 2 | 0 | €47.55 | €52.75 | 10.931% |
| PTC Therapeutics Inc. | 16 | 9 | 2 | 1 | €28.00 | €41.81 | 49.336% |
| United Therapeutics | 21 | 0 | 2 | 0 | €287.90 | €288.66 | 0.264% |
| Neurocrine Bioscience | 33 | 0 | 2 | 0 | €128.30 | €140.87 | 9.795% |
| Emergent Biosolutions Inc. | 4 | 3 | 2 | 0 | €7.32 | €7.45 | 1.814% |
| Acadia Pharmaceuticals | 30 | 1 | 2 | 0 | €14.93 | €31.00 | 107.659% |
| Viatris Inc. | 3 | 0 | 2 | 0 | €9.54 | €12.25 | 28.353% |
| Exelixis Inc. | 19 | 0 | 1 | 0 | €20.38 | €26.01 | 27.607% |
| Agios Pharmaceuticals Inc. | 8 | 1 | 1 | 1 | €39.00 | €43.87 | 12.485% |
| Medpace Holdings Inc | 12 | 0 | 1 | 0 | €370.80 | €419.82 | 13.220% |
| Iovance Biotherapeutics Inc. | 22 | 2 | 1 | 0 | €6.70 | €26.25 | 291.619% |
| Nektar Therapeutics | 4 | 1 | 1 | 0 | €1.18 | €2.40 | 104.082% |
| Alkermes plc | 14 | 2 | 1 | 0 | €22.40 | €34.08 | 52.146% |
| Ultragenyx Pharmaceutical Inc. | 22 | 1 | 1 | 0 | €37.40 | €85.51 | 128.640% |
| Amicus Therapeutics Inc. | 7 | 0 | 0 | 0 | €9.15 | €17.64 | 92.762% |
| Novocure Ltd | 1 | 1 | 0 | 0 | €15.48 | - | - |
| Blueprint Medicines Corp | 1 | 0 | 0 | 0 | €103.00 | - | - |
| Icon plc | 21 | 0 | 0 | 0 | €295.90 | €324.79 | 9.763% |